{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:45:24Z","timestamp":1792017924278,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010434","name":"\"la Caixa\" Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"DOI":"10.1038\/s41591-026-04671-5","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:56:39Z","timestamp":1792014999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7448-7822","authenticated-orcid":false,"given":"Francesca","family":"Zacchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Imbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejo","family":"Rodriguez-Vida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Mellado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1180-5604","authenticated-orcid":false,"given":"Gisela","family":"Mir Arnau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9106-0687","authenticated-orcid":false,"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Climent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4666-0666","authenticated-orcid":false,"given":"Manuel J.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0178-4567","authenticated-orcid":false,"given":"Angel","family":"Borque-Fernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5343-8300","authenticated-orcid":false,"given":"Paula","family":"Gonzalez-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhudit","family":"Perez-Escuredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Izquierdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Isabel","family":"Saez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heura","family":"Domenech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Arce-Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6235-4897","authenticated-orcid":false,"given":"Bernardo","family":"Herrera-Imbroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Planas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Font","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Cresta Morgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3944-0203","authenticated-orcid":false,"given":"Victor","family":"Esquefa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4316-3952","authenticated-orcid":false,"given":"Julian","family":"Brandariz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6482-2623","authenticated-orcid":false,"given":"Nicolas","family":"Anselmino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8241-1430","authenticated-orcid":false,"given":"Patricia","family":"Troncoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0763-7947","authenticated-orcid":false,"given":"Monica","family":"Aguilera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2888-6512","authenticated-orcid":false,"given":"Ana","family":"Vivancos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1380-0990","authenticated-orcid":false,"given":"Paolo","family":"Nuciforo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Casanova-Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7900-4239","authenticated-orcid":false,"given":"Eduard","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9983-5934","authenticated-orcid":false,"given":"Joan","family":"Carles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3805-7307","authenticated-orcid":false,"given":"Amado J.","family":"Zurita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5336-2548","authenticated-orcid":false,"given":"Joaquin","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"4671_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"4671_CR2","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong, A. J. et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 37, 2974\u20132986 (2019).","journal-title":"J. Clin. Oncol."},{"key":"4671_CR3","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi, K. N. et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J. Clin. Oncol. 39, 2294\u20132303 (2021).","journal-title":"J. Clin. Oncol."},{"key":"4671_CR4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/ijc.34018","volume":"151","author":"ND James","year":"2022","unstructured":"James, N. D. et al. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). Int. J. Cancer 151, 422\u2013434 (2022).","journal-title":"Int. J. Cancer"},{"key":"4671_CR5","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO-24-01798","volume":"42","author":"F Saad","year":"2024","unstructured":"Saad, F. et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J. Clin. Oncol. 42, 4271\u20134281 (2024).","journal-title":"J. Clin. Oncol."},{"key":"4671_CR6","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi, K. et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 20, 686\u2013700 (2019).","journal-title":"Lancet Oncol."},{"key":"4671_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373, 737\u2013746 (2015).","journal-title":"N. Engl. J. Med."},{"key":"4671_CR8","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","volume":"30","author":"NW Clarke","year":"2019","unstructured":"Clarke, N. W. et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann. Oncol. 30, 1992\u20132003 (2019).","journal-title":"Ann. Oncol."},{"key":"4671_CR9","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker, C. C. et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392, 2353\u20132366 (2018).","journal-title":"Lancet"},{"key":"4671_CR10","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi, K. et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet 399, 1695\u20131707 (2022).","journal-title":"Lancet"},{"key":"4671_CR11","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith, M. R. et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N. Engl. J. Med. 386, 1132\u20131142 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4671_CR12","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1158\/1078-0432.CCR-25-4823","volume":"32","author":"ES Antonarakis","year":"2026","unstructured":"Antonarakis, E. S. et al. Carboplatin, cabazitaxel, and abiraterone in high-volume metastatic castration-sensitive prostate cancer: the CASCARA phase II study. Clin. Cancer Res. 32, 2403\u20132412 (2026).","journal-title":"Clin. Cancer Res."},{"key":"4671_CR13","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215\u20131228 (2015).","journal-title":"Cell"},{"key":"4671_CR14","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard, C. C. et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N. Engl. J. Med. 375, 443\u2013453 (2016).","journal-title":"N. Engl. J. Med."},{"key":"4671_CR15","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.18.00358","volume":"37","author":"E Castro","year":"2019","unstructured":"Castro, E. et al. PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 37, 490\u2013503 (2019).","journal-title":"J. Clin. Oncol."},{"key":"4671_CR16","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","volume":"35","author":"D Olmos","year":"2024","unstructured":"Olmos, D. et al. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes. Ann. Oncol. 35, 458\u2013472 (2024).","journal-title":"Ann. Oncol."},{"key":"4671_CR17","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.annonc.2025.05.534","volume":"36","author":"D Olmos","year":"2025","unstructured":"Olmos, D. et al. BRCA1\/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes. Ann. Oncol. 36, 1190\u20131202 (2025).","journal-title":"Ann. Oncol."},{"key":"4671_CR18","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913\u2013917 (2005).","journal-title":"Nature"},{"key":"4671_CR19","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo, J. et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373, 1697\u20131708 (2015).","journal-title":"N. Engl. J. Med."},{"key":"4671_CR20","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J De Bono","year":"2020","unstructured":"De Bono, J. et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 382, 2091\u20132102 (2020).","journal-title":"N. Engl. J. Med."},{"key":"4671_CR21","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi, K. et al. Rucaparib or physician\u2019s choice in metastatic prostate cancer. N. Engl. J. Med. 388, 719\u2013732 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4671_CR22","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200043","volume":"1","author":"NW Clarke","year":"2022","unstructured":"Clarke, N. W. et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 1, EVIDoa2200043 (2022).","journal-title":"NEJM Evid."},{"key":"4671_CR23","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1158\/1078-0432.CCR-24-1402","volume":"30","author":"M Hussain","year":"2024","unstructured":"Hussain, M. et al. Abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer with DNA repair defects (BRCAAway). Clin. Cancer Res. 30, 4318\u20134328 (2024).","journal-title":"Clin. Cancer Res."},{"key":"4671_CR24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","volume":"402","author":"N Agarwal","year":"2023","unstructured":"Agarwal, N. et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet 402, 291\u2013303 (2023).","journal-title":"Lancet"},{"key":"4671_CR25","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","volume":"41","author":"KN Chi","year":"2023","unstructured":"Chi, K. N. et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J. Clin. Oncol. 41, 3339\u20133351 (2023).","journal-title":"J. Clin. Oncol."},{"key":"4671_CR26","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1200\/JCO.23.02105","volume":"42","author":"J Fallah","year":"2024","unstructured":"Fallah, J. et al. Efficacy of poly(ADP-ribose) polymerase inhibitors by individual genes in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer: a US Food and Drug Administration pooled analysis. J. Clin. Oncol. 42, 1687\u20131698 (2024).","journal-title":"J. Clin. Oncol."},{"key":"4671_CR27","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1038\/s41591-025-03961-8","volume":"31","author":"G Attard","year":"2025","unstructured":"Attard, G. et al. Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. Nat. Med. 31, 4109\u20134118 (2025).","journal-title":"Nat. Med."},{"key":"4671_CR28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2604126","volume":"395","author":"N Agarwal","year":"2026","unstructured":"Agarwal, N. et al. PARP and androgen-signaling inhibition plus ADT in metastatic prostate cancer. N. Engl. J. Med. 395, 427\u2013439 (2026).","journal-title":"N. Engl. J. Med."},{"key":"4671_CR29","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aam7479","volume":"10","author":"L Li","year":"2017","unstructured":"Li, L. et al. Androgen receptor inhibitor-induced \u2018BRCAness\u2019 and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci. Signal 10, eaam7479 (2017).","journal-title":"Sci. Signal"},{"key":"4671_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00393-y","volume":"8","author":"M Asim","year":"2017","unstructured":"Asim, M. et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat. Commun. 8, 374 (2017).","journal-title":"Nat. Commun."},{"key":"4671_CR31","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","volume":"3","author":"WR Polkinghorn","year":"2013","unstructured":"Polkinghorn, W. R. et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov. 3, 1245\u20131253 (2013).","journal-title":"Cancer Discov."},{"key":"4671_CR32","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1158\/2159-8290.CD-13-0108","volume":"3","author":"JF Goodwin","year":"2013","unstructured":"Goodwin, J. F. et al. A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov. 3, 1254\u20131271 (2013).","journal-title":"Cancer Discov."},{"key":"4671_CR33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2515790122","volume":"123","author":"NA Traphagen","year":"2026","unstructured":"Traphagen, N. A. et al. Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer. Proc. Natl Acad. Sci. USA 123, e2515790122 (2026).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4671_CR34","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1158\/1541-7786.MCR-23-0358","volume":"21","author":"S Hasterok","year":"2023","unstructured":"Hasterok, S. et al. The androgen receptor does not directly regulate the transcription of DNA damage response genes. Mol. Cancer Res. 21, 1329\u20131341 (2023).","journal-title":"Mol. Cancer Res."},{"key":"4671_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.101937","volume":"6","author":"S Arce-Gallego","year":"2025","unstructured":"Arce-Gallego, S. et al. Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence. Cell Rep. Med. 6, 101937 (2025).","journal-title":"Cell Rep. Med."},{"key":"4671_CR36","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.euo.2025.04.015","volume":"8","author":"AJ Zurita","year":"2025","unstructured":"Zurita, A. J. et al. Randomized phase 2 trial of presurgical androgen deprivation therapy with or without axitinib in prostate cancer presenting with lymph node metastasis. Eur. Urol. Oncol. 8, 1010\u20131019 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"4671_CR37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","volume":"87","author":"S Gillessen","year":"2025","unstructured":"Gillessen, S. et al. Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur. Urol. 87, 157\u2013216 (2025).","journal-title":"Eur. Urol."},{"key":"4671_CR38","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad, F. et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1094\u20131108 (2023).","journal-title":"Lancet Oncol."},{"key":"4671_CR39","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","volume":"34","author":"KN Chi","year":"2023","unstructured":"Chi, K. N. et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann. Oncol. 34, 772\u2013782 (2023).","journal-title":"Ann. Oncol."},{"key":"4671_CR40","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.euo.2026.01.008","volume":"9","author":"A-J Inderjeeth","year":"2026","unstructured":"Inderjeeth, A.-J. et al. Radiographic progression without prostate-specific antigen progression in metastatic hormone-sensitive prostate cancer: a retrospective analysis of the ENZAMET trial (ANZUP 1304). Eur. Urol. Oncol. 9, 396\u2013403 (2026).","journal-title":"Eur. Urol. Oncol."},{"key":"4671_CR41","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.euo.2024.04.009","volume":"8","author":"W Fukuokaya","year":"2025","unstructured":"Fukuokaya, W. et al. Radiographic progression without corresponding prostate-specific antigen progression in patients with metastatic castration-sensitive prostate cancer receiving apalutamide: secondary analysis of the TITAN trial. Eur. Urol. Oncol. 8, 263\u2013269 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"4671_CR42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.annonc.2025.10.004","volume":"37","author":"K Fizazi","year":"2026","unstructured":"Fizazi, K. et al. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann. Oncol. 37, 53\u201368 (2026).","journal-title":"Ann. Oncol."},{"key":"4671_CR43","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","volume":"8","author":"P-M Morice","year":"2021","unstructured":"Morice, P.-M. et al. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol. 8, e122\u2013e134 (2021).","journal-title":"Lancet Haematol."},{"key":"4671_CR44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1001\/jamaoncol.2020.5161","volume":"7","author":"K Jensen","year":"2021","unstructured":"Jensen, K. et al. Association of clonal hematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference. JAMA Oncol. 7, 107\u2013110 (2021).","journal-title":"JAMA Oncol."},{"key":"4671_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44514-2","volume":"15","author":"MC Markowski","year":"2024","unstructured":"Markowski, M. C. et al. Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial. Nat. Commun. 15, 14 (2024).","journal-title":"Nat. Commun."},{"key":"4671_CR46","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1001\/jamaoncol.2024.3074","volume":"10","author":"CH Marshall","year":"2024","unstructured":"Marshall, C. H. et al. Olaparib without androgen deprivation for high-risk biochemically recurrent prostate cancer following prostatectomy: a nonrandomized controlled trial. JAMA Oncol. 10, 1400\u20131408 (2024).","journal-title":"JAMA Oncol."},{"key":"4671_CR47","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1158\/1078-0432.CCR-24-1304","volume":"31","author":"H Dev","year":"2025","unstructured":"Dev, H. et al. Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): a window study into the effects of olaparib \u00b1 degarelix in primary prostate cancer. Clin. Cancer Res. 31, 2347\u20132357 (2025).","journal-title":"Clin. Cancer Res."},{"key":"4671_CR48","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1470-2045(26)00066-5","volume":"27","author":"M Kayani","year":"2026","unstructured":"Kayani, M. et al. On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials. Lancet Oncol. 27, 625\u2013636 (2026).","journal-title":"Lancet Oncol."},{"key":"4671_CR49","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2307\/2529712","volume":"31","author":"SJ Pocock","year":"1975","unstructured":"Pocock, S. J. & Simon, R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31, 103\u2013115 (1975).","journal-title":"Biometrics"},{"key":"4671_CR50","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1080\/03610918.2019.1619765","volume":"50","author":"M Jin","year":"2021","unstructured":"Jin, M., Polis, A. & Hartzel, J. Algorithms for minimization randomization and the implementation with an R package. Commun. Stat. Simul. Comput. 50, 3077\u20133087 (2021).","journal-title":"Commun. Stat. Simul. Comput."},{"key":"4671_CR51","doi-asserted-by":"publisher","unstructured":"Zacchi, F. et al. Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer (ZZ-FIRST): a randomized phase 2 clinical trial [data set]. Zenodo https:\/\/doi.org\/10.5281\/zenodo.21218835 (2026).","DOI":"10.5281\/zenodo.21218835"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04671-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04671-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04671-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:56:41Z","timestamp":1792015001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04671-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":51,"alternative-id":["4671"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04671-5","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"24 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.C. reports advisory role for AstraZeneca, Bayer, Johnson & Johnson, Lilly, Medscape, Merck Serono, MSD Oncology, Novartis and Pfizer; honoraria from Astellas Pharma, AstraZeneca, Bayer, Johnson & Johnson, Medscape, Novartis, Peerview, Pfizer, Casen Recordati and Telix; research funding from Bayer, Johnson & Johnson and Pfizer; and travel\/accommodation support from AstraZeneca, Bayer, Johnson & Johnson, Pfizer and Casen Recordati. She is also involved in several pharma-sponsored and investigator-initiated clinical trials. A.R.-V. reports serving in an advisory role for Pfizer, Bristol Myers Squibb, Merck Serono, MSD Oncology, Astellas Pharma, Johnson & Johnson, AstraZeneca, Bayer, Novartis and Ipsen; and receiving honoraria or travel expenses from Pfizer, MSD Oncology, Astellas Pharma, Merck Serono, Bristol Myers Squibb, Johnson & Johnson, AstraZeneca, Bayer, Novartis and Ipsen. A.B.-F. has received fees for participation in training events from Astellas Pharma, AstraZeneca, Bayer, GP Pharm, Ipsen, Johnson & Johnson, MSD Oncology, fees for advisory meetings (Advisory Board) from Astellas Pharma, AstraZeneca, Bayer, Johnson & Johnson, and support for meeting attendance from Astellas Pharma, AstraZeneca, Bayer, Ipsen, Johnson & Johnson and Casen Recordati. J.A.G., P.G.-A., J.P.-E. and V.I. declare full-time employment at MEDSIR. B.H.-I. has received academic grants, research funding from Johnson & Johnson and Myriad Genetics; consulting\/advisory fees from AstraZeneca, Johnson & Johnson, Bristol Myers Squibb, MSD Oncology, Ipsen, Casen Recordati, Abbott, Astellas Pharma, Bayer, Accord and Pfizer; honoraria\/speaker fees from Astellas Pharma, Bayer, Johnson & Johnson and Ipsen; and travel support from Johnson & Johnson, Bayer, Casen Recordati, Ipsen, Astellas Pharma, AstraZeneca, Accord and Pfizer. D.L. reports advisory role for AstraZeneca, MSD Oncology and Johnson & Johnson; honoraria from Astellas Pharma, AstraZeneca, Bayer, Johnson & Johnson, Pfizer and MSD Oncology; research funding from Bayer; and travel\/accommodation support from AstraZeneca, Bayer, Johnson & Johnson, Pfizer and MSD Oncology. P.N. reports consulting fees from Discovery Life Sciences (former Targos Molecular Pathology GmbH) and institutional research funding from AstraZeneca, ADC Therapeutics, Anaveon, Alentis Therapeutics and Peptomyc. J.C. declares consulting or advisory role for Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Ipsen, Johnson & Johnson, MSD Oncology, Novartis (AAA), Pfizer and Sanofi; speakers\u2019 Bureau for Astellas Pharma, Bayer, Johnson & Johnson and Sanofi; and travel, accommodations and expenses from BMS, Ipsen, Roche, AstraZeneca and Bayer. A.J.Z. has received research funding from Pfizer, AstraZeneca, Astellas Pharma, X4 Pharma, Infinity, Merck Serono, ABX, Curium and Fusion; consulting fees from Pfizer, Astellas Pharma, Incyte, Bayer, Exelixis, Dendreon and Foundation Medicine; and speaker\u2019s fees and travel support from Pfizer, Janssen, HIKMA, Amedco, CancerNet, McKesson Specialty Health and DAVA. J.M. has served as advisor for AstraZeneca, Amunix\/VIR, Bayer, Daiichi-Sankyo, Guardant Health, Johnson & Johnson, MSD Oncology, Pfizer and Roche; he has participated in speakers\u2019 bureau for AstraZeneca, Johnson & Johnson, Pfizer and Novartis; he is involved as investigator in several pharma-sponsored and investigator-initiated clinical trials and has received research funding from AstraZeneca, Pfizer and Amgen to VHIO (institution). The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}